Vancomycin is an antibiotic used to treat serious bacterial infections that resist other drugs. It works exclusively against gram-positive bacteria, making it one of the most important weapons against MRSA (methicillin-resistant Staphylococcus aureus) and other dangerous resistant infections. It comes in two forms, intravenous and oral, and each treats a completely different set of conditions.
How Vancomycin Works
Bacteria survive by building and maintaining a protective outer wall. Vancomycin kills bacteria by blocking a critical step in that construction process. It physically binds to the building blocks of the bacterial wall, preventing them from linking together. Without a functioning wall, the bacterium can’t hold itself together and dies.
This mechanism only works against gram-positive bacteria, a broad category that includes staph, strep, and several other species responsible for serious infections. Vancomycin has no effect on gram-negative bacteria, which have a different outer structure that the drug can’t penetrate. That distinction matters because it means vancomycin is always chosen for specific, identified infections rather than used as a catch-all antibiotic.
Infections Treated With IV Vancomycin
When vancomycin is given through a vein, it circulates through the bloodstream and reaches infected tissue throughout the body. The FDA approves IV vancomycin for five categories of serious infection in both adults and children:
- Bloodstream infections (septicemia): Bacteria circulating in the blood, particularly MRSA, are one of the primary reasons vancomycin is prescribed. Most of the clinical research on vancomycin dosing comes from patients with complicated bloodstream infections.
- Heart valve infections (infective endocarditis): Bacteria colonizing the inner lining of the heart or its valves require prolonged antibiotic courses, and vancomycin is a standard choice when resistant organisms are involved.
- Skin and soft tissue infections: Deep or spreading skin infections caused by MRSA or other resistant gram-positive bacteria that don’t respond to first-line antibiotics.
- Bone infections (osteomyelitis): Infections in bone tissue are notoriously difficult to clear and often require weeks of IV antibiotic therapy.
- Lower respiratory tract infections: This includes certain cases of pneumonia caused by gram-positive organisms, particularly hospital-acquired pneumonia where MRSA is suspected.
IV vancomycin is the go-to drug for MRSA specifically because few other antibiotics reliably kill this organism. It also covers methicillin-resistant Staphylococcus epidermidis (a common cause of infections on implanted devices), penicillin-resistant pneumococcus, and several other resistant gram-positive species including streptococci and enterococci.
Oral Vancomycin for Gut Infections
Oral vancomycin treats a completely different problem. When swallowed, the drug barely absorbs into the bloodstream. Instead, it stays in the gut, which makes it ideal for infections that live there. Oral vancomycin is FDA-approved for two conditions: Clostridioides difficile (C. diff) infection and staph-related inflammation of the intestinal lining.
C. diff is the more common reason by far. This bacterium causes severe, often relentless diarrhea, typically after a course of other antibiotics has wiped out the normal gut flora. Current guidelines from the Infectious Diseases Society of America recommend oral vancomycin four times daily for 10 to 14 days for both mild and severe C. diff infections. It’s important to understand that oral vancomycin cannot treat infections elsewhere in the body. It won’t help with bloodstream infections, pneumonia, or bone infections because it never reaches those tissues in meaningful amounts. The reverse is also true: IV vancomycin doesn’t work for C. diff because it doesn’t concentrate in the gut.
Which Bacteria Vancomycin Covers
Vancomycin’s spectrum is broad within the gram-positive world. It’s active against staphylococci (including MRSA and MRSE), streptococci, enterococci, pneumococci, and several less common organisms like Corynebacterium, Listeria, and Bacillus species. It also kills gram-positive anaerobes, bacteria that thrive without oxygen, including Clostridium species and oral anaerobes like Peptostreptococcus.
Where vancomycin draws a hard line is gram-negative bacteria. It has zero activity against them. This means infections caused by E. coli, Pseudomonas, Klebsiella, or other gram-negative organisms require different antibiotics entirely. In practice, doctors often pair vancomycin with a gram-negative antibiotic when they don’t yet know which bacteria are causing a severe infection.
Side Effects to Know About
The most recognizable side effect of IV vancomycin is sometimes called “red man syndrome,” a flushing reaction that causes redness, itching, and sometimes a rash across the face, neck, and upper body. This is not a true allergy. It happens when the drug triggers certain immune cells to release histamine, and it’s directly related to how fast the infusion runs. Slowing the infusion rate to at least 100 minutes per gram typically prevents it entirely.
The more serious concern is kidney injury. Studies show that vancomycin-associated acute kidney injury occurs in roughly 5% to 43% of patients, depending on the population studied and the definition used. Several factors increase that risk: higher drug levels in the blood, longer treatment courses, and receiving certain other antibiotics at the same time. Because of this, medical teams monitor vancomycin blood levels closely during treatment. The current recommended target is an AUC (a measure of total drug exposure over 24 hours) between 400 and 600 for serious MRSA infections. Staying within this range balances effectiveness against the infection with a lower risk of kidney damage. Levels above approximately 470 in the first 48 hours have been independently linked to higher rates of kidney problems.
Why Blood Level Monitoring Matters
Unlike many antibiotics where a standard dose works for most people, vancomycin is unpredictable. Two patients of similar size can end up with very different drug levels from the same dose. Too little drug in the bloodstream risks treatment failure, while too much increases the chance of kidney injury. This is why vancomycin requires regular blood draws during treatment to check levels and adjust doses accordingly.
For patients, this means you can expect periodic blood tests throughout a vancomycin course, especially in the first few days. Your care team uses these results to fine-tune your dose. This monitoring is standard practice, not a sign that something is going wrong. It’s one of the reasons vancomycin is almost always given in a hospital or through a supervised outpatient infusion program rather than simply prescribed and sent home.